Adagrasib is currently under comparison with docetaxel in a Phase III trial (NCT04685135; KRYSTAL-12) for previously treated KRAS-G12C NSCLC, and is also under investigation as a first-line treatment in a Phase II trial (NCT04613596; KRYSTAL-7). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.